Roland Mertelsmann

Last updated

Roland Mertelsmann
Roland Mertelsmann.png
Born (1944-10-05) 5 October 1944 (age 80)
Hameln, Germany
Known forHematology, oncology, gene therapy, stem cell transplantation
Scientific career
FieldsOncology, hematology
Institutions University of Freiburg

Roland Mertelsmann is a hematologist, oncologist and professor emeritus [1] at the University Medical Center Freiburg, Department of Oncology, Hematology and Stem Cell Transplantation in Freiburg im Breisgau, Germany. Mertelsmann is known for his scientific works in the fields of hematology, oncology, gene therapy and stem cell transplantation.

Contents

Biography

Mertelsmann studied medicine at the University of Göttingen 1966–68. He was a doctoral candidate at the Max Planck Institute for Experimental Medicine at Heinrich Matthaei in Göttingen 1966–68. He continued his medical education at the School of Medicine King's College London and at the Columbia-Presbyterian Medical Center, New York 1968–78. After graduating from Hamburg University Medical School and receiving his MD degree, he became Research Fellow at the Department of Developmental Hematopoiesis and received a special fellowship in Hematology and Clinical Oncology at Memorial Sloan-Kettering Cancer Center (MSKCC), 1976–78. There he contributed to the isolation of the blood stimulating growth factor G-CSF, which leads to a faster recovery of white blood cells after chemotherapy and radiation therapy protecting patients better against severe infections. From 1978 to 86 he was clinical assistant physician at MSKCC, then assistant attending physician and associate attending physician at the Memorial Hospital of Sloan-Kettering Cancer Center. He was promoted from assistant professor of medicine to associate professor of medicine at Cornell University, New York. In 1985, he returned to Germany and was appointed professor and head of the 3rd Medical Clinic Hematology and Oncology at the University of Mainz, Germany, University Medical Center. 1989 he accepted a professorship at the University of Freiburg. At Freiburg University Medical Center he became the director of the Department for Medicine I, Oncology, Hematology and Stem Cell Transplantation. He retired in 2012. [2]

During his career Mertelsmann recruited and promoted young scientists. Several leading positions at universities and in the industry were occupied with former team members of Mertelsmann. In 2008 he founded the International Master Program in Biomedical Sciences, [3] a cooperation of the universities of Freiburg and Buenos Aires, educating and training international master students in biomedicine. In 2014 he initiated the foundation of the journal JOSHA, [4] a novel internet platform to access the broad diversity of important discoveries and creativity in the fields of science, humanities and arts. Mertelsmann published more than 400 articles in medical journals.[ citation needed ]

Scientific contribution

Molecular and cellular mechanisms of malignancy- First description of a human RNA polymerase

After discovery of the genetic code by Heinrich Matthaei and Marshall Nirenberg (1962), Mertelsmann began his research for his medical doctorate as a medical student in Heinrich Matthaei's Laboratory at the Max-Planck-Institute for experimental Medicine in Göttingen, Germany, demonstrating and characterizing for the first time a human RNA-Polymerase. [5] Since nucleic acid synthesis is an important target for chemotherapeutic agents, he subsequently investigated in his team together with various colleagues, DNA-Polymerases, especially terminal deoxynucleotidyl transferase (TdT), and RNA-Polymerases as diagnostic and prognostic markers in leukemias and lymphomas. [6]

Studies of the Pathophysiology and Molecular Biology of Cancer Cells

The "Plasticity" of hematopoietic stem cells (HSC), i.e. the differentiation of HSC into cells of other organs, [7] was intensively studied with Alexandros Spyridonidis [8] in patients after allogeneic bone marrow transplantation. These studies demonstrated conclusively, that this phenomenon can be observed in these patients, but is a rare event. Molecular mechanisms of B-cell neoplasias [9] [10] were investigated together with Binder, Trepel and Dierks, the pathogenic significance of granulocytes in Graft-versus-host disease with Zeiser and his colleagues. [11]

Clinical Significance of the Leukemia Phenotype

As a member of the clinical (Director Bayard Clarkson) and laboratory teams (Director Malcolm A.S. Moore), he carried out a systematic analysis of all patients with acute myeloid leukemia (AML) treated at MSKCC, defining the prognostic and predictive parameters of cell cytology, cell growth in vitro and enzymatic markers. [12] [13] By using all techniques available at the time for phenotypic characterization of leukemia cells, he was successful in discovering and describing novel subentities of acute leukemias. [14] [15]

New therapeutic Modalities

In Cooperation with Karl Welte and his colleagues at MSKCC the purification and molecular and biological characterization of cytokines, important regulators of cell division, differentiation and migration, were the focus of his work in the following years at MSKCC. Interleukin-2 [16] as well as G-CSF [17] were purified to homogeneity, First translational and clinical studies of cytokines followed. [18] Since experiments in murine models demonstrated that local production by gene transduced cells produced a stronger and more specific immune response than a systemic application, e.g. of Interleukin-2, this strategy was also pursued by his group in Phase I clinical trials. [19] [20] [21] These studies contributed to the later, successful clinical implementation of gene therapy for this and other indications.[ citation needed ]

Clinical Studies

In clinical trials for patients with leukemias and lymphomas at the MSKCC [22] and subsequently in German and European clinical trial groups, [23] [24] new therapeutic concepts were studied including classical chemotherapies as well as novel therapeutic strategies. [25] [26] For some rare, generally lethal cancers, the innovative use of rapidly recycling classical chemotherapy combinations followed by immediate High Dose Chemotherapy with HSC transplantation, led to long term remission and probably cures, which had not been seen with other therapies and in historical controls. [27]

As clinical oncologist Mertelsmann also search for novel strategies to not only prolong life, but to increase quality of life. The systematic development of aerobic training programs for cancer patients undergoing chemotherapy and bone morrow transplantation [28] was highly successful and is now being used in many cancer centers worldwide.[ citation needed ]

Accusation of scientific misconduct

Mertelsmann was involved in a scientific misconduct affair in 1997. The complaint focussed on the falsification of laboratory data. An investigation commission did not prove the active participation of Mertelsmann. [29]

Academic memberships

Mertelsmann is or was member of many international scientific organizations or journals, among them many years at the journals European Journal of Cancer and Annals of Hematology. He is a foundation member of the Comprehensive Cancer Center Freiburg (CCCF), Initiator and director of the International Biomedical Exchange Program (IMEP), founder of the ARGER-Foundation, [30] editor of the SRC-SDARF-UJDRF Joint Programme in Stem Cell Research, Stockholm and president of the International Association for Comparative Research on Leukemia and related Diseases (IACRLD).[ citation needed ]

Other select memberships:

Awards

Publications

Articles in journals

Books (selection)

See also

Roland Mertelsmann in:

Related Research Articles

<span class="mw-page-title-main">Lymphoma</span> Hematologic cancer that affects lymphocytes

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.

<span class="mw-page-title-main">Chronic lymphocytic leukemia</span> Bone marrow cancer in which lymphocytes are overproduced

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell. Many people do not have any symptoms when they are first diagnosed. Those with symptoms may experience fevers, fatigue, night sweats, and weight loss. These patients may also have painless lymph node swelling, enlargement of the spleen, and/or a low red blood cell count (anemia). These symptoms may worsen over time.

<span class="mw-page-title-main">Granulocyte colony-stimulating factor</span> Mammalian protein found in humans

Granulocyte colony-stimulating factor, also known as colony-stimulating factor 3, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.

<span class="mw-page-title-main">Hematopoietic stem cell transplantation</span> Medical procedure to replace blood or immune stem cells

Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood, in order to replicate inside a patient and produce additional normal blood cells. HSCT may be autologous, syngeneic, or allogeneic.

<span class="mw-page-title-main">Adult T-cell leukemia/lymphoma</span> Human disease

Adult T-cell leukemia/lymphoma is a rare cancer of the immune system's T-cells caused by human T cell leukemia/lymphotropic virus type 1 (HTLV-1). All ATL cells contain integrated HTLV-1 provirus further supporting that causal role of the virus in the cause of the neoplasm. A small amount of HTLV-1 individuals progress to develop ATL with a long latency period between infection and ATL development. ATL is categorized into 4 subtypes: acute, smoldering, lymphoma-type, chronic. Acute and Lymphoma-type are known to particularly be aggressive with poorer prognosis.

Waldenström macroglobulinemia is a type of cancer affecting two types of B cells: lymphoplasmacytoid cells and plasma cells. Both cell types are white blood cells. It is characterized by having high levels of a circulating antibody, immunoglobulin M (IgM), which is made and secreted by the cells involved in the disease. Waldenström macroglobulinemia is an "indolent lymphoma" and a type of lymphoproliferative disease which shares clinical characteristics with the indolent non-Hodgkin lymphomas. It is commonly classified as a form of plasma cell dyscrasia, similar to other plasma cell dyscrasias that, for example, lead to multiple myeloma. Waldenström macroglobulinemia is commonly preceded by two clinically asymptomatic but progressively more pre-malignant phases, IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia. The Waldenström macroglobulinemia spectrum of dysplasias differs from other spectrums of plasma cell dyscrasias in that it involves not only aberrant plasma cells but also aberrant lymphoplasmacytoid cells and that it involves IgM while other plasma dyscrasias involve other antibody isoforms.

<span class="mw-page-title-main">Interleukin 7</span> Growth factor secreted by stromal cells in the bone marrow and thymus.

Interleukin 7 (IL-7) is a protein that in humans is encoded by the IL7 gene.

Lymphomatoid granulomatosis (LYG or LG) is a very rare lymphoproliferative disorder first characterized in 1972. Lymphomatoid means lymphoma-like and granulomatosis denotes the microscopic characteristic of the presence of granulomas with polymorphic lymphoid infiltrates and focal necrosis within it.

<span class="mw-page-title-main">CD135</span> Protein found in humans

Cluster of differentiation antigen 135 (CD135) also known as fms like tyrosine kinase 3, receptor-type tyrosine-protein kinase FLT3, or fetal liver kinase-2 (Flk2) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. CD135 is the receptor for the cytokine Flt3 ligand (FLT3L).

Richter's transformation (RT), also known as Richter's syndrome, is the conversion of chronic lymphocytic leukemia (CLL) or its variant, small lymphocytic lymphoma (SLL), into a new and more aggressively malignant disease. CLL is the circulation of malignant B lymphocytes with or without the infiltration of these cells into lymphatic or other tissues while SLL is the infiltration of these malignant B lymphocytes into lymphatic and/or other tissues with little or no circulation of these cells in the blood. CLL along with its SLL variant are grouped together in the term CLL/SLL.

<span class="mw-page-title-main">Blastic plasmacytoid dendritic cell neoplasm</span> Medical condition

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN constitutes 0.44% of all hematological malignancies.

Marcel R.M. van den Brink is a Dutch oncologist and researcher known for his research in hematopoietic stem cell transplantation for cancer patients.

David G. Maloney is an oncologist and researcher at Fred Hutchinson Cancer Research Center and the University of Washington who specializes in developing targeted immunotherapies for the treatment of blood cancers.

Clonal hypereosinophilia, also termed primary hypereosinophilia or clonal eosinophilia, is a grouping of hematological disorders all of which are characterized by the development and growth of a pre-malignant or malignant population of eosinophils, a type of white blood cell that occupies the bone marrow, blood, and other tissues. This population consists of a clone of eosinophils, i.e. a group of genetically identical eosinophils derived from a sufficiently mutated ancestor cell.

<span class="mw-page-title-main">Camidanlumab tesirine</span> Antibody-drug conjugate

Camidanlumab tesirine is an antibody-drug conjugate (ADC) composed of a human antibody that binds to the protein CD25, conjugated to a pyrrolobenzodiazepine dimer toxin. The experimental drug, developed by ADC Therapeutics is being tested in clinical trials for the treatment of B-cell Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL), and for the treatment of B-cell acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

<span class="mw-page-title-main">Shimon Slavin</span> Israeli professor of medicine

Shimon Slavin is an Israeli professor of medicine. He pioneered immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation to cure hematological malignancies and solid tumors. He also used hematopoietic stem cells to induce transplantation tolerance to bone marrow and organ allografts.

<span class="mw-page-title-main">Nirali N. Shah</span> American physician-scientist and pediatric hematologist-oncologist

Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.

<span class="mw-page-title-main">Brunangelo Falini</span> Italian hematologist, academic and researcher

Brunangelo Falini is an Italian hematologist, academic and researcher. He is a Full Professor of Hematology, and Head of the Institute of Hematology and Bone Marrow Transplantation at University of Perugia.

Christopher Hourigan is a physician-scientist known for work on measurable residual disease in acute myeloid leukemia.

Bayard Delafield Clarkson Sr. is an American physician, hematologist, and oncologist.

References

  1. ↑ Mertelsmann, Roland. "Curriculum Vitae Professor Dr. Drs. h.c. Roland Heinrich Mertelsmann" (PDF). www.uniklinik-freiburg.de. Archived (PDF) from the original on 27 June 2024.
  2. 1 2 3 Roland Mertelsmann CV
  3. ↑ IMBS
  4. ↑ JOSHA
  5. ↑ R. Mertelsmann: Purification and some properties of a soluble DNA-dependent. RNA polymerase from nuclei of human placenta. In: Eur. J. Biochem. 1969 Jun;9(3), S. 311–318. PMID   5795512
  6. ↑ R. Mertelsmann, B. Koziner, D. A. Filippa, E. Grossbard, G. Incefy, M. A. Moore, B. D. Clarkson: Clinical significance of TdT, cell surface markers and CFU-C in 297 patients with hematopoietic neoplasias. In: Haematol Blood Transfus. 1979;23, S. 131–138. PMID   317470. Prof. em. Dr. Drs. h.c. Roland Mertelsmann
  7. ↑ R. Mertelsmann: Plasticity of bone marrow-derived stem cells. In: J Hematother Stem Cell Res. 2000 Dec;9(6), S. 957–960. Review. PMID   11177610
  8. ↑ A. Spyridonidis, R. Mertelsmann, J. Finke: Hematopoietic stem cell transplantation: more than just hematopoietic? In: J Cancer Res Clin Oncol. 2004 Mar;130(3), S. 127–134. Epub 2004 Jan 16. Review. PMID   14727105
  9. ↑ M. Binder, F. Müller, M. Frick, C. Wehr, F. Simon, B. Leistler, H. Veelken, R. Mertelsmann, M. Trepel: CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. In: Blood. 2013 Jan 3;121(1), S. 239–241. doi:10.1182/blood-2012-09-454439. PMID   23287626
  10. ↑ C. Dierks, J. Grbic, K. Zirlik, R. Beigi, N. P. Englund, G. R. Guo, H. Veelken, M. Engelhardt, R. Mertelsmann, J. F. Kelleher, P. Schultz, M. Warmuth: Essential role of stromally induced hedgehog signaling in B-cell malignancies. In: Nat Med. 2007 Aug;13(8), S. 944–951. Epub 2007 Jul 15. PMID   17632527.
  11. ↑ L. Schwab, L. Goroncy, S. Palaniyandi, S. Gautam, A. Triantafyllopoulou, A. Mocsai, W. Reichardt, F. J. Karlsson, S. V. Radhakrishnan, K. Hanke, A. Schmitt-Graeff, M. Freudenberg, F. D. von Loewenich, P. Wolf, F. Leonhardt, N. Baxan, D. Pfeifer, O. Schmah, A. Schönle, S. F. Martin, R. Mertelsmann, J. Duyster, J. Finke, M. Prinz, P. Henneke, H. Häcker, G. C. Hildebrandt, G. Häcker, R. Zeiser: Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. In: Nat Med. 2014 Jun;20(6), S. 648–654. doi:10.1038/nm.3517. Epub 2014 May 18. PMID   24836575
  12. ↑ R. Mertelsmann, M. A. Moore, B. Clarkson: Leukemia cell phenotype and prognosis: an analysis of 519 adults with acute leukemia. In: Blood Cells. 1982;8(3), S. 561–583. PMID   6984348
  13. ↑ R. Mertelsmann, H. Tzvi Thaler, L. To, T. S. Gee, S. McKenzie, P. Schauer, A. Friedman, Z. Arlin, C. Cirrincione, B. Clarkson: Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. In: Blood. 1980 Nov;56(5), S. 773–781. PMID   6932977.
  14. ↑ N. Ciobanu, M. Andreeff, B. Safai, B. Koziner, R. Mertelsmann: Lymphoblastic neoplasia in a homosexual patient with Kaposi’s sarcoma. In: Ann Intern Med. 1983 Feb;98(2), S. 151–155. PMID   6572044.
  15. ↑ R. Mertelsmann, B. Koziner, R. Ralph, D. Filippa, S. McKenzie, Z. A. Arlin, T. S. Gee, M. A. Moore, B. D. Clarkson: Evidence for distinct lymphocytic and monocytic populations in a patient with terminal transferase—positive acute leukemia. In: Blood. 1978 Jun;51(6), S. 1051–1056. PMID   274159
  16. ↑ K. Welte, C. Y. Wang, R. Mertelsmann, S. Venuta, S. P. Feldman, M. A. Moore: Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. In: J Exp Med. 1982 Aug 1;156(2), S. 454–464. PMID   6980256 PMC   2186775
  17. ↑ K. Welte, E. Platzer, L. Lu, J. L. Gabrilove, E. Levi, R. Mertelsmann, M. A. Moore: Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. In: Proc Natl Acad Sci U S A. 1985 Mar;82(5), S. 1526–1530. PMID   3871951 PMC   397296
  18. ↑ R. Mertelsmann, K. Welte, C. Sternberg, R. O'Reilly, M. A. Moore, B. D. Clarkson, H. F. Oettgen: Treatment of immunodeficiency with interleukin-2: initial exploration. In: J Biol Response Mod. 1984 Oct;3(5), S. 483–490. PMID   6334136
  19. ↑ H. Glimm, K. Flügge, D. Möbest, V. M. Hofmann, J. Postmus, R. Henschler, W. Lange, J. Finke, H. P. Kiem, G. Schulz, F. Rosenthal, R. Mertelsmann, C. von Kalle: Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium. In: Hum Gene Ther. 1998 Apr 10;9(6), S. 771–778. PMID   9581900.
  20. ↑ H. Veelken, A. Mackensen, M. Lahn, G. Köhler, D. Becker, B. Franke, U. Brennscheidt, P. Kulmburg, F. M. Rosenthal, H. Keller, J. Hasse, W. Schultze-Seemann, E. H. Farthmann, R. Mertelsmann, A. Lindemann: A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. In: Int J Cancer. 1997 Jan 27;70(3), S. 269–277. PMID   9033626
  21. ↑ G. Stingl, E. B. Brŏcker, R. Mertelsmann, K. Wolff, S. Schreiber, E. Kămpgen, A. Schneeberger, W. Dummer, U. Brennscheid, H. Veelken, M. L. Birnstiel, K. Zatloukal, W. Schmidt, G. Maass, E. Wagner, M. Baschle, M. Giese, E. R. Kempe, H. A. Weber, T. Voigt: Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. In: Hum Gene Ther. 1996 Mar 1;7(4), S. 551–563. PMID   8800750
  22. ↑ R. Mertelsmann, R. L. Drapkin, T. S. Gee, S. Kempin, S. Passe, H. T. Thaler, Z. Arlin, M. Dowling, P. Dufour, S. McKenzie, L. To, E. Comacho, H. F. Oettgen, J. H. Burchenal, B. Clarkson: Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol. In: Cancer. 1981 Nov 15;48(10), S. 2136–2142. PMID   6170414
  23. ↑ M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits, M. Mohren, E. Lengfelder, M. Reiser, C. Nickenig, M. Clemens, N. Peter, C. Bokemeyer, H. Eimermacher, A. Ho, M. Hoffmann, R. Mertelsmann, L. Trümper, L. Balleisen, R. Liersch, B. Metzner, F. Hartmann, B. Glass, V. Poeschel, N. Schmitz, C. Ruebe, A. C. Feller, M. Loeffler: German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). In: Lancet Oncol. 2008 Feb;9(2), S. 105–116. doi : 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. PMID   18226581
  24. ↑ O. Determann, E. Hoster, G. Ott, H. Wolfram Bernd, C. Loddenkemper, M. Leo Hansmann, T. E. Barth, M. Unterhalt, W. Hiddemann, M. Dreyling, W. Klapper: European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. In: Blood. 2008 Feb 15;111(4), S. 2385–2387. Epub 2007 Dec 12. PMID   18077791
  25. ↑ H. P. Koeffler, D. Heitjan, R. Mertelsmann, J. E. Kolitz, P. Schulman, L. Itri, P. Gunter, E. Besa: Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. In: Blood. 1988 Mar;71(3), S. 703–708. PMID   3278754. 309: W. Hiddemann, H. Kreutzmann, K. Straif, W. D. Ludwig, R. Mertelsmann, M. Planker, R. Donhuijsen-Ant, E. Lengfelder, Z. Arlin, T. Büchner: High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. In: Semin Oncol. 1987 Jun;14(2 Suppe 1), S. 73–77. PMID   3473685
  26. ↑ E. J. Gold, R. H. Mertelsmann, L. M. Itri, T. Gee, Z. Arlin, S. Kempin, B. Clarkson, M. A. Moore: Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. In: Cancer Treat Rep. 1983 Nov;67(11), S. 981–986. PMID   6580071
  27. ↑ L. Houet, I. Möller, M. Engelhardt, G. Köhler, H. Schmidt, D. Herchenbach, M. Schnitzler, A. Schmitt-Graeff, A. A. Jungbluth, R. Mertelsmann, B. Rumstadt, C. F. Waller: Long-term remission after CD34+-selected PBSCT in a patient with advanced intra-abdominal desmoplastic small round-cell tumor. In: Bone Marrow Transplant. 2010 Apr;45(4), S. 793–795. doi:10.1038/bmt.2009.226. Epub 2009 Aug 31. PMID   19718066 PMC   3147145
  28. ↑ F. Dimeo, H. Bertz, J. Finke, S. Fetscher, R. Mertelsmann, J. Keul: An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. In: Bone Marrow Transplant. 1996 Dec;18(6), S. 1157–1160. PMID   8971388.
  29. ↑ Klaus Koch: Fälschungsskandal – Verjährt und zugenäht. auf: aerzteblatt.de
  30. ↑ ARGER Foundation
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.